Retatrutide: GLP-1 + GIP + Glucagon (Triple Agonist) Retatrutide (LY3437943) keeps the same two receptors as tirzepatide, then adds a third: glucagon
[unverified no linkable source] Dermatica review of GHK-Cu evidence (collagen, TGF-/MMP, 12-week topical cosmetic trial)
Medication adjustments under medical supervision
depot formulations sustain release over 1-6 months) ~2-4 hours (estimated, topical peptide) ~2-4 hours (estimated
It refers to evaluating whether GLP-1 receptor agonists could benefit individuals who have normal body weight but still show significant cardiometabolic risk factors such as insulin resistance, dyslipidemia, or cardiovascular disease
In full-thickness skin wounds, increased VEGF expression and accelerated new blood vessel formation in granulation tissue were demonstrated